▶ Beta blockers, selective are predicted to increase the risk of
peripheral vasoconstriction when given with
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the risk of ergotism when given with
▶ Cobicistat is predicted to increase the risk of ergotism when
given with ergometrine. Avoid.rTheoretical
▶ Crizotinib is predicted to increase the risk of ergotism when
given with ergometrine.rTheoretical
▶ Ergometrine is predicted to increase the risk of ergotism when
given with dopamine receptor agonists (cabergoline, pergolide).
1452 Enzalutamide — Ergometrine BNF 78
▶ Esketamine is predicted to increase the risk of elevated blood
▶ Grapefruit juice is predicted to increase the exposure to
▶ HIV-protease inhibitors are predicted to increase the risk of
▶ Idelalisib is predicted to increase the risk of ergotism when
given with ergometrine. Avoid.rTheoretical
▶ Imatinib is predicted to increase the risk of ergotism when
given with ergometrine.rTheoretical
▶ Ketamine is predicted to increase the risk of elevated blood
pressure when given with ergometrine.rTheoretical
▶ Letermovir is predicted to increase the concentration of
ergometrine. Avoid.rTheoretical
▶ Macrolides (clarithromycin) are predicted to increase the risk of
▶ Macrolides (erythromycin) are predicted to increase the risk of
ergotism when given with ergometrine.rTheoretical
▶ Netupitant is predicted to increase the risk of ergotism when
given with ergometrine.rTheoretical
▶ Nilotinib is predicted to increase the risk of ergotism when
given with ergometrine.rTheoretical
▶ Ergometrine potentially increases the risk of peripheral
vasoconstriction when given with sympathomimetics, inotropic
▶ Ergometrine is predicted to increase the risk of peripheral
vasoconstriction when given with sympathomimetics,
vasoconstrictor (noradrenaline/norepinephrine).rAnecdotal
▶ Almotriptan is predicted to increase the risk of
vasoconstriction when given with ergotamine. Ergotamine
should be taken at least 24 hours before or 6 hours after
▶ Antiarrhythmics (dronedarone) are predicted to increase the
risk of ergotism when given with ergotamine.rTheoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the effects of
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the risk of ergotism when given with
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the risk of ergotism when given with
ergotamine. Avoid.rTheoretical
▶ Antifungals, azoles (miconazole) are predicted to increase the
exposure to ergotamine. Avoid.oTheoretical
▶ Aprepitant is predicted to increase the risk of ergotism when
given with ergotamine.rTheoretical
▶ Beta blockers, non-selective are predicted to increase the risk
of peripheral vasoconstriction when given with ergotamine.
▶ Beta blockers, selective are predicted to increase the risk of
peripheral vasoconstriction when given with
is predicted to decrease the effects of ergotamine.
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the risk of ergotism when given with
▶ Ceritinib is predicted to increase the exposure to ergotamine.
▶ Cobicistat is predicted to increase the risk of ergotism when
given with ergotamine. Avoid.rTheoretical
▶ Crizotinib is predicted to increase the risk of ergotism when
given with ergotamine.rTheoretical
▶ Ergotamine is predicted to increase the risk of ergotism when
given with dopamine receptor agonists (bromocriptine,
cabergoline). Avoid.oTheoretical
▶ Ergotamine is predicted to increase the risk of ergotism when
given with dopamine receptor agonists (pergolide).o
is predicted to decrease the effects of ergotamine.
▶ Eletriptan increases the risk of vasoconstriction when given
ergotamine. Separate administration by 24 hours.r
▶ Enzalutamide is predicted to decrease the effects of
▶ Grapefruit juice is predicted to increase the exposure to
▶ HIV-protease inhibitors are predicted to increase the risk of
ergotism when given with ergotamine. Avoid.rTheoretical
▶ Idelalisib is predicted to increase the risk of ergotism when
given with ergotamine. Avoid.rTheoretical
▶ Imatinib is predicted to increase the risk of ergotism when
given with ergotamine.rTheoretical
▶ Letermovir is predicted to increase the concentration of
ergotamine. Avoid.rTheoretical
▶ Macrolides (clarithromycin) are predicted to increase the risk of
ergotism when given with ergotamine. Avoid.rTheoretical
▶ Macrolides (erythromycin) are predicted to increase the risk of
ergotism when given with ergotamine.rTheoretical
is predicted to decrease the effects of ergotamine.
▶ Naratriptan is predicted to increase the risk of
vasoconstriction when given with ergotamine. Separate
administration by 24 hours.rTheoretical
▶ Netupitant is predicted to increase the risk of ergotism when
given with ergotamine.rTheoretical
is predicted to decrease the effects of ergotamine.
▶ Nilotinib is predicted to increase the risk of ergotism when
given with ergotamine.rTheoretical
▶ Palbociclib is predicted to increase the exposure to
ergotamine. Adjust dose.oTheoretical
▶ Ribociclib (high-dose) is predicted to increase the exposure to
ergotamine. Avoid.oTheoretical
is predicted to decrease the effects of ergotamine.
▶ Rizatriptan is predicted to increase the risk of vasoconstriction
when given with ergotamine. Ergotamine should be taken at
least 24 hours before or 6 hours after
▶ Rucaparib is predicted to increase the exposure to ergotamine.
Monitor and adjust dose.oStudy
▶ St John’s Wort is predicted to decrease the effects of
▶ Sumatriptan increases the risk of vasoconstriction when given
with ergotamine. Ergotamine should be taken at least 24 hours
before or 6 hours after sumatriptan.rStudy
▶ Ticagrelor is predicted to increase the exposure to ergotamine.
Eribulin → see TABLE 15 p. 1378 (myelosuppression), TABLE 12 p. 1378
(peripheral neuropathy), TABLE 9 p. 1377 (QT-interval prolongation)
FOOD AND LIFESTYLE Dose adjustment may be necessary if
smoking started or stopped during treatment.
▶ Antacids are predicted to decrease the absorption of erlotinib.
Antacids should be taken 4 hours before or 2 hours after
▶ Antiarrhythmics (amiodarone, dronedarone) are predicted to
increase the exposure to erlotinib.oTheoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
to erlotinib. Avoid or adjust erlotinib dose, p. 979.rStudy
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure to
erlotinib.o ▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to slightly increase the exposure to erlotinib. Use
with caution and adjust dose.oStudy
is predicted to increase the exposure to erlotinib.
▶ Erlotinib is predicted to increase the risk of gastrointestinal
BNF 78 Ergometrine — Erlotinib 1453
is predicted to decrease the exposure to erlotinib.
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to erlotinib.oTheoretical
is predicted to increase the exposure to erlotinib.
▶ Cobicistat is predicted to slightly increase the exposure to
erlotinib. Use with caution and adjust dose.oStudy
▶ Combined hormonal contraceptives slightly increase the
erlotinib. Monitor side effects and adjust dose.
▶ Corticosteroids increase the risk of gastrointestinal
perforation when given with erlotinib.rTheoretical
increases the anticoagulant effect of coumarins.
is predicted to increase the exposure to erlotinib.
is predicted to decrease the exposure to erlotinib.
▶ Enzalutamide is predicted to decrease the exposure to
erlotinib. Avoid or adjust erlotinib dose, p. 979.rStudy
▶ Grapefruit juice is predicted to increase the exposure to
▶ H2 receptor antagonists are predicted to decrease the exposure
to erlotinib. Erlotinib should be taken 2 hours before or
10 hours after H2 receptor antagonists.oStudy
▶ HIV-protease inhibitors are predicted to slightly increase the
erlotinib. Use with caution and adjust dose.
▶ Idelalisib is predicted to slightly increase the exposure to
erlotinib. Use with caution and adjust dose.oStudy
is predicted to increase the exposure to erlotinib.
is predicted to increase the exposure to erlotinib.
▶ Macrolides (azithromycin, erythromycin) are predicted to
increase the exposure to erlotinib.oTheoretical
▶ Macrolides (clarithromycin) are predicted to slightly increase
erlotinib. Use with caution and adjust dose.
▶ Mexiletine slightly increases the exposure to erlotinib. Monitor
side effects and adjust dose.oStudy
▶ Mitotane is predicted to decrease the exposure to erlotinib.
Avoid or adjust erlotinib dose, p. 979.rStudy
is predicted to increase the exposure to erlotinib.
is predicted to decrease the exposure to erlotinib.
is predicted to increase the exposure to erlotinib.
▶ Erlotinib is predicted to increase the risk of gastrointestinal
perforation when given with NSAIDs.rTheoretical
▶ Erlotinib is predicted to increase the risk of bleeding events
when given with phenindione.rTheoretical
▶ Proton pump inhibitors are predicted to slightly decrease the
exposure to erlotinib. Avoid.oStudy
▶ Quinolones (ciprofloxacin) slightly increase the exposure to
erlotinib. Monitor side effects and adjust dose.oStudy
is predicted to increase the exposure to erlotinib.
▶ Rifampicin is predicted to decrease the exposure to erlotinib.
Avoid or adjust erlotinib dose, p. 979.rStudy
▶ SSRIs (fluvoxamine) are predicted to increase the exposure to
. Monitor side effects and adjust dose.o ▶ St John’s Wort is predicted to decrease the exposure to
is predicted to increase the exposure to erlotinib.
Ertugliflozin → see TABLE 14 p. 1378 (antidiabetic drugs), TABLE 8
Esketamine → see TABLE 8 p. 1376 (hypotension), TABLE 11 p. 1377 (CNS
▶ Esketamine is predicted to increase the risk of seizures when
given with aminophylline. Avoid.rTheoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
to esketamine. Adjust dose.oTheoretical → Also see
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to
▶ Cobicistat is predicted to increase the exposure to esketamine.
▶ Enzalutamide is predicted to decrease the exposure to
esketamine. Adjust dose.oTheoretical
▶ Esketamine is predicted to increase the risk of elevated blood
▶ HIV-protease inhibitors are predicted to increase the exposure
to esketamine. Adjust dose.oStudy
▶ Idelalisib is predicted to increase the exposure to esketamine.
▶ Macrolides (clarithromycin) are predicted to increase the
exposure to esketamine. Adjust dose.oStudy
▶ Mitotane is predicted to decrease the exposure to esketamine.
▶ Rifampicin is predicted to decrease the exposure to
esketamine. Adjust dose.oTheoretical
▶ Esketamine is predicted to increase the risk of seizures when
given with theophylline. Avoid.rTheoretical
Eslicarbazepine → see antiepileptics
Esmolol → see beta blockers, selective
Esomeprazole → see proton pump inhibitors
Estramustine → see alkylating agents
▶ Anakinra is predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
etanercept. Avoid.rTheoretical
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
etanercept. Public Health England advises avoid (refer to
▶ Cinacalcet increases the risk of hypocalcaemia when given
with etelcalcetide. Avoid.rTheoretical
▶ Isoniazid increases the risk of optic neuropathy when given
Ethosuximide → see antiepileptics
Etomidate → see TABLE 8 p. 1376 (hypotension), TABLE 11 p. 1377 (CNS
▶ Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin,
oxcarbazepine, perampanel, phenobarbital, phenytoin,
primidone, rufinamide, topiramate) are predicted to decrease
the efficacy of etonogestrel. For FSRH guidance, see
Contraceptives, interactions p. 794.rTheoretical
▶ Aprepitant is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Bosentan is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Efavirenz is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Fosaprepitant is predicted to decrease the efficacy of
etonogestrel. For FSRH guidance, see Contraceptives,
interactions p. 794.rTheoretical
▶ Griseofulvin decreases the efficacy of etonogestrel. For FSRH
Contraceptives, interactions p. 794.r
1454 Erlotinib — Etonogestrel BNF 78
▶ HIV-protease inhibitors (ritonavir) are predicted to decrease the
efficacy of etonogestrel. For FSRH guidance, see
Contraceptives, interactions p. 794.rTheoretical
▶ Modafinil is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Nevirapine is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Rifabutin is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Rifampicin is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ St John’s Wort is predicted to decrease the efficacy of
etonogestrel. MHRA advises avoid. For FSRH guidance, see
Contraceptives, interactions p. 794.rTheoretical
▶ Sugammadex is predicted to decrease the efficacy of
. Use additional contraceptive precautions.r
▶ Ulipristal is predicted to decrease the efficacy of etonogestrel.
Etoposide → see TABLE 15 p. 1378 (myelosuppression)
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the efficacy of
▶ Ciclosporin increases the exposure to etoposide. Monitor and
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
etoposide. Public Health England advises avoid (refer to Green
slightly increases the exposure to etoposide.
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
